We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A Blue-Chip Starter Portfolio: GlaxoSmithKline plc, HSBC Holdings plc And ARM Holdings plc

How do GlaxoSmithKline plc (LON:GSK), HSBC Holdings plc (LON:HSBA), ARM Holdings plc (LON:ARM) and the UK’s other seven industry giants shape up as a starter portfolio?

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Every quarter I take a look at the top FTSE 100 companies in each of the index’s 10 industry sectors, to see how they shape up as a potential ‘starter portfolio’.

The table below shows the top 10 heavyweights and their valuations, based on forecast 12-month price-to-earnings (P/E) ratios and dividend yields.

Should you buy HSBC Holdings shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

Company Industry Recent share
price (p)
P/E Yield (%)
ARM Holdings (LSE: ARM) Technology 1,026 28.8 1.0
BAE Systems Industrials 501 12.6 4.3
British American Tobacco Consumer Goods 4,083 17.6 4.1
GlaxoSmithKline (LSE: GSK) Health Care 1,414 16.3 5.7
HSBC Holdings (LSE: HSBA) Financials 432 9.5 8.2
National Grid Utilities 979 15.7 4.6
Rio Tinto Basic Materials 1,943 19.7 4.4
Royal Dutch Shell Oil & Gas 1,683 18.8 7.7
Tesco Consumer Services 190 21.4 0.8
Vodafone Telecommunications 220 37.1 5.2

To get a feel for overall value, the table below shows the average P/E and yield at selected previous quarterly review dates. The averages exclude ARM, with its typically elevated tech-sector P/E, and also Vodafone, whose P/E has been anomalous since its mega-sale of Verizon Wireless.

  P/E Yield (%)
April 2016 16.4 5.0
January 2016 13.7 6.0
October 2015 13.7 5.6
July 2015 14.4 5.2
April 2015 14.9 4.8
April 2014 12.8 4.6
April 2013 12.4 4.4

The big jump in the group P/E from three months ago is rather startling. So, what’s going on?

Well, for one thing, most of the companies’ share prices have risen since the start the year, pushing their P/Es up. This has been significantly compounded in the case of Rio Tinto and Shell, whose 12-month forward earnings have at the same time been drastically reduced by analysts. The market appears to be looking beyond 12 months with this pair, as the City number crunchers are forecasting a big rebound in earnings for 2017 on the back of improving oil and metals prices, as well as the benefits of the BG acquisition in Shell’s case.

Certainly, these two natural resources companies could deliver decent long-term returns from here, although the shares may be volatile for a while yet, and it may be possible to pick them up at a cheaper price than today.

Drugs comeback

An expected return to growth by pharmaceuticals giant GlaxoSmithKline isn’t dependent on such unpredictable things as oil and metals prices. After a number of tough years of patent expiries putting a dent in profits, Glaxo is on the brink of a growth comeback, and a P/E of 16.3 and a dividend yield of 5.7% look appealing.

An additional attraction is the possibility of shareholder value being unlocked by Glaxo spinning off its consumer healthcare business, or undertaking other restructuring activity, particularly after a recent announcement that current chief executive Sir Andrew Witty will be stepping down in March next year.

Cheap if no China crisis

HSBC also appears worth highlighting, standing out as the only stock on a P/E in single digits, and also possessing the highest yield at 8.2%. The consensus earnings and dividend forecasts of City analysts are relatively optimistic, but the market is evidently much more nervous. Concerns about HSBC’s exposure to China and the bank’s lack of headway on reducing costs have sent the shares to multi-year lows.

If there were to be a real meltdown in China, HSBC would certainly be hit hard. It’s not without risk, but HSBC is on such a cheap rating that it could prove to be outstanding value right now, based on current projections for the economy of the People’s Republic, and if the bank’s self-help measures finally begin to bear fruit.

Value in tech champion

The super-efficient chip designs of ARM Holdings have long been ubiquitous in mobile phones, and have driven tremendous earnings growth over the years. I believe the opportunity for the company provided by the so-called Internet of Things could help to drive further impressive earnings growth in the coming decades.

I consider this world-class British technology company to be good value when its P/E is below 30 — as it is now. Furthermore, the P/E isn’t quite as high as it seems, when adjusted for the hundreds of millions in cash and short-term deposits on ARM’s balance sheet.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended ARM Holdings, GlaxoSmithKline, and HSBC Holdings. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up as a woman counts out modern British banknotes.
Investing Articles

How to buy growth stocks at below-market prices

Don’t want to pay market prices for growth stocks? Here's a sneaky strategy investors can use to get deals at…

Read more »

CEO Mark Zuckerberg at F8 2019 event
Investing Articles

Are Meta shares at the start of a comeback?

Shares in Meta Platforms have been held back by the firm’s high-risk approach to AI. But is this the moment…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

With dividend yields averaging above 7%, are these 2 UK shares worth considering?

Muhammad Cheema looks at two UK shares: ITV and Legal & General. With yields of 6.1% and 8.1%, should investors…

Read more »

Close-up as a woman counts out modern British banknotes.
Investing Articles

How much do you need to invest in dividend stocks to be able to retire?

Some 77% of people in the UK won't have enough income to manage a moderate retirement. Here’s how dividend stocks…

Read more »

Abstract bull climbing indicators on stock chart
Investing Articles

FTSE 250 stock CMC’s shares have rocketed 51%! What’s going on?

CMC Markets' shares have surged by double-digits today after a strong full-year trading update. Is the FTSE 250 company now…

Read more »

A row of satellite radars at night
Investing Articles

Will I buy SpaceX at £100 a share in my SIPP?

Ben McPoland is considering adding SpaceX stock to his SIPP on 12 June. Might this be a no-brainer buy-and-hold opportunity?

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

Aberdeen shares are back in the FTSE 100 — is this turnaround stock just getting started?

Following its return to the FTSE 100, Andrew Mackie examines whether Aberdeen's shares could be on the cusp of a…

Read more »

Shot of an young mixed-race woman using her cellphone while out cycling through the city
Investing Articles

Down 65% with a 5.65% yield! Is this dividend share a once-in-a-decade buy? 

Harvey Jones says this dividend share is still posting decent profits at a challenging time. Its low valuation and high…

Read more »